DrugPatentWatch Database Preview

PF PRISM CV Company Profile

« Back to Dashboard

What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?

PF PRISM CV has sixteen approved drugs.

There are forty-six US patents protecting PF PRISM CV drugs.

Summary for PF PRISM CV

US Patents:	46
Tradenames:	12
Ingredients:	11
NDAs:	16

Drugs and US Patents for PF PRISM CV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-003	Oct 27, 2017		RX	Yes	No	6,002,008		Y	Y
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes	8,975,242		Y
Pf Prism Cv	LYRICA CR	pregabalin	TABLET, EXTENDED RELEASE;ORAL	209501-001	Oct 11, 2017		RX	Yes	No	RE41920
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-001	Sep 4, 2012		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes

Expired US Patents for PF PRISM CV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	VFEND	voriconazole	INJECTABLE;IV (INFUSION)	021267-001	May 24, 2002	5,116,844
Pf Prism Cv	VFEND	voriconazole	FOR SUSPENSION;ORAL	021630-001	Dec 19, 2003	5,364,938
Pf Prism Cv	VFEND	voriconazole	TABLET;ORAL	021266-002	May 24, 2002	5,773,443
Pf Prism Cv	LYRICA	pregabalin	CAPSULE;ORAL	021446-006	Dec 30, 2004	5,563,175
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-004	Jan 25, 2010	5,100,899*PED
Pf Prism Cv	VFEND	voriconazole	INJECTABLE;IV (INFUSION)	021267-001	May 24, 2002	5,134,127

Paragraph IV (Patent) Challenges for PF PRISM CV drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	0.5 mg and 1 mg		2010-05-10
	Tablets	5 mg		2016-11-07
	Oral Solution	20 mg/mL		2010-05-19
	Tablets	50 mg and 200 mg		2008-04-14
	For Injection	50 mg per vial		2009-06-15
	Tablets	1 mg and 2 mg		2009-12-17
	Extended-release Tablets	330 mg		2018-01-29
	Extended-release Tablets	330 mg		2018-01-29
	Tablets	100mg and 500mg		2016-09-06
	Tablets	1 mg and 5 mg		2018-02-23
	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg		2008-12-30
	For Injection	200 mg/vial		2008-09-12
	Oral Suspension	40 mg/mL		2010-10-08
	Injection	25 mg/mL, 1.8 mL vial		2011-05-25
	Tablets	0.5 mg		2010-08-25
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02
	Extended-release Tablets	82.5 mg and 165 mg		2018-02-02

International Patents for PF PRISM CV Drugs

Country	Document Number	Estimated Expiration
Eurasian Patent Organization	200401216
Eurasian Patent Organization	200501236
Denmark	1266899
Spain	2263640
Japan	2000513029
Japan	4619346

Supplementary Protection Certificates for PF PRISM CV Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
00055	Netherlands		PRODUCT NAME: SIROLIMUS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT; NATL. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: CH CH/55243 20000926
8	Finland
2004017	Lithuania		PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RûGðTIS)
9	Finland
2013003,C1218348	Lithuania		PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903
442	Luxembourg		91442, EXPIRES: 20210926

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pf Prism Cv